Ken Griffin Savara Inc Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$3.66 - $5.34 $334,524 - $488,076
91,400 Added 22850.0%
91,800 $369,000
Q1 2024

May 15, 2024
BUY
$4.19 - $5.59 $1,676 - $2,236
400 New
400 $1,000
Q3 2023

Nov 14, 2023
BUY
$2.97 - $3.88 $3,564 - $4,656
1,200 New
1,200 $4,000
Q1 2023

May 15, 2023
BUY
$1.6 - $2.82 $11,360 - $20,022
7,100 New
7,100 $13,000

Others Institutions Holding SVRA

# of Institutions
145
Shares Held
147M
Call Options Held
280K
Put Options Held
798K
View Full List

About Savara Inc

SVRA Quotes by TradingView
  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $479M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email